U.S. Markets closed

Tricida, Inc. (TCDA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.11-0.24 (-4.49%)
At close: 4:00PM EDT
5.12 +0.01 (0.20%)
After hours: 05:19PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.35
Open5.34
Bid5.00 x 1100
Ask5.11 x 1100
Day's Range4.94 - 5.34
52 Week Range3.74 - 28.18
Volume386,168
Avg. Volume364,692
Market Cap256.894M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Tricida (TCDA) Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Tricida (TCDA) Sees Hammer Chart Pattern: Time to Buy?

    Tricida (TCDA) has been struggling lately, but the selling pressure may be coming to an end soon

  • Have Insiders Been Buying Tricida, Inc. (NASDAQ:TCDA) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Tricida, Inc. (NASDAQ:TCDA) Shares This Year?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Here's Why Tricida Shares Plummeted Today
    Motley Fool

    Here's Why Tricida Shares Plummeted Today

    Shares of Tricida (NASDAQ: TCDA) are down 30% at 1:33 p.m. EST today after the Food and Drug Administration denied the company's appeal of a complete response letter (CRL) that the agency issued for Tricida's marketing application for veverimer as a treatment for chronic kidney disease. A CRL, like the one Tricida received in August 2020, is essentially a rejection letter from the FDA with instructions on what data the agency would need to see for the drug to eventually get approved. Tricida was trying to get veverimer approved under the accelerated approval pathway, which uses surrogate endpoints, such as biomarkers, to predict clinical outcomes.